[The anticonvulsive action of the intranigral administration of the delta sleep-inducing peptide].
Shandra. O A OA; Hodlevs'kyĭ. L S LS; Mazarati. A M AM; Oleshko. A A AA; Vast'ianov. R S RS; Mykhal'ova. I I II
Key Findings
- DSIP injected into the substantia nigra reticular part suppresses picrotoxin‑ and corazol‑induced convulsions in rats.
- The seizure‑blocking effect is blocked by naloxone (an opioid antagonist) and enhanced by haloperidol (a dopamine blocker) and yohimbine (an alpha‑2 antagonist).
- DSIP does not affect seizures triggered by strychnine, indicating a selective mechanism.
Practical Outcomes
- The study suggests DSIP may have anti‑seizure properties via opioid activation and dopamine suppression, but it was tested only with direct brain injections in animals. For biohackers, there is no clear, safe way to replicate this effect with oral or peripheral DSIP use, so it does not yet translate into a usable protocol for seizure prevention or performance enhancement.
Summary
In rats, injecting the peptide delta sleep‑inducing peptide (DSIP) directly into a specific brain region (the substantia nigra) reduced seizures caused by certain chemicals, but not all types of seizures. The anti‑seizure effect depended on opioid pathways and was boosted when dopamine activity was blocked.
Abstract
It is shown that injection of delta sleep-inducing peptide (DSIP) into the substantia nigra reticular part (SNrp) suppresses generalized convulsive activity induced in rats by picrotoxin and corazol injection but exerts no influence on the strichnine-induced seizures. The analogous DSIP injection causes the antiepileptic action in rats kindled through picrotoxin injections. The DSIP intranigral anticonvulsant action is blocked by naloxon and enhanced by haloperidol and yohimbin. It can be concluded that DSIP anticonvulsant action may be realized due to activation of SNrp-dependent opioid mechanisms and suppression of dopaminergic ones.
Study Information
pubmed
1992